Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Patel, JN; Jiang, C; Owzar, K; Hertz, DL; Mulkey, FA; Kelly, WK; Halabi, S; Furukawa, Y; Lassiter, C; Dorsey, SG; Friedman, PN; Small, EJ; Carducci, MA; Mahoney, JF; Kelley, MJ; Nakamura, Y; Kubo, M; Ratain, MJ; Morris, MJ; McLeod, HL

Published Date

  • July 15, 2016

Published In

  • Experimental and Molecular Therapeutics

Published By

Digital Object Identifier (DOI)

  • 10.1158/1538-7445.am2016-2037

Conference Name

  • Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA